FTC Concludes Acular Patent Investigation
This article was originally published in The Pink Sheet Daily
Executive SummaryThe Federal Trade Commission has concluded its investigation into whether Allergan unfairly prevented generic competition for Acular (ketorolac ophthalmic solution .5%)
You may also be interested in...
Association for Accessible Medicines’ interim leader is General Counsel Jeffrey Francer; Chip Davis’ four-and-half year tenure included a total rebrand of the association, a significant legislative victory with the CREATES act – and an abrupt departure for the Healthcare Distribution Alliance.
PDUFA and GDUFA negotiations are expected to begin first, as they usually take the longest to complete, and will be followed by BsUFA talks.
Healthy Adult Opportunity initiative (don’t call it block grants) adopts some, but not all, of Medicare Part D’s protected classes, allowing states to exclude some drugs from coverage in the expansion Medicaid population to drive additional savings.